Sugi Predict

Sugi Predict / Compounds / SCHEMBL725809

SCHEMBL725809

SCHEMBL725809

COc1cc(N)c(Cl)cc1C(N)=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.73
▸ NPC1 O15118 1/20 0.58
▸ HTR4 Q13639 7/20 0.55
▸ CYP1A2 P05177 2/20 0.55
▸ CYP2D6 P10635 2/20 0.55
▸ HTR3A P46098 2/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ ADRA2A P08913 2/20 0.53
▸ ADRA2C P18825 2/20 0.53
▸ HTR2A P28223 2/20 0.53
▸ HTR2C P28335 2/20 0.53
▸ HTR2B P41595 2/20 0.53
▸ HTR3E A5X5Y0 1/20 0.53
▸ SLC22A1 O15245 1/20 0.53
▸ HTR3B O95264 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL724940 0.98 GAA (0.71) GAANPC1HTR4CYP1A2CYP2D6
SCHEMBL11689093 0.89 HTR4 (0.67) GAANPC1HTR4CYP1A2CYP2D6
Ethyl Acetate SCHEMBL5925561 0.87 GAA (0.57) GAAHTR4CYP1A2CYP2D6HTR3A
SCHEMBL5951822 0.86 GAA (0.58) GAANPC1HTR4CYP1A2CYP2D6
SCHEMBL7280230 0.86 GAA (0.73) GAANPC1HTR4CYP1A2CYP2D6
SCHEMBL7351910 0.86 GAA (0.73) GAANPC1HTR4CYP1A2CYP2D6
SCHEMBL99019 0.86 GAA (0.73) GAANPC1HTR4CYP1A2CYP2D6
SCHEMBL3876555 0.85 GAA (0.53) GAANPC1CYP3A4SMN1; SMN2ALDH1A1
SCHEMBL9793655 0.85 KDM4E (0.53) GAANPC1HTR4CYP1A2CYP2D6
SCHEMBL15579474 0.85 GAA (0.55) GAAHTR4CYP1A2CYP2D6HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560955-A2 NOVEL BENZAMIDE DERIVATIVES Dong-A Pharm.Co., Ltd. (KR) 2013-02-27 — — EP claimed
WO-2011132901-A2 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM.CO., LTD. (KR) 2011-10-27 — — WO claimed
WO-2002036113-A1 COMPOSITION COMPRISING: SEROTONIN RECEPTOR ANTAGONISTS (5HT-2, 5HT-3) AND AGONIST (5HT-4) RESPIRATORIUS AB (SE) 2002-05-10 — — WO claimed
WO-2001095902-A9 A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS — 2002-04-25 — — WO claimed
WO-2001095902-A1 A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS RESPIRATORIUS AB (SE) 2001-12-20 — — WO claimed
US-4962115-A Stimulate motility of gastrointestinal system JANSSEN PHARMACEUTICA N.V. (BE) 1990-10-09 — — US claimed
WO-2021225968-A1 LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-11 — — WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 — — US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 — — US disclosed
WO-1999005106-A1 NOVEL BENZAMIDE DERIVATIVES STIMULATING HIGH AND LOW GASTROINTESTINAL MOTRICITY LABORATOIRES JACQUES LOGEAIS (FR) 1999-02-04 — — WO disclosed
WO-1999005133-A1 BENZAMIDE CYCLOALKYL STIMULATING HIGH AND LOW GASTROINTESTINAL MOTRICITY LABORATOIRES JACQUES LOGEAIS (FR) 1999-02-04 — — WO disclosed
EP-0596933-A1 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-05-18 — — EP disclosed
WO-1993002677-A1 5-HT4 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1993-02-18 — — WO disclosed
US-5137895-A Antiemetic, anxiolytic, gastric emptying and serotonin modulating activity A. H. ROBINS COMPANY, INCORPORATED (US) 1992-08-11 — — US disclosed
EP-0210893-B1 BENZAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE Laboratoires DELAGRANGE, Société Anonyme (FR) 1990-10-03 — — EP disclosed
CN-1031701-A The improvement of preparation N-substituted benzamide FORDONAL SA (ES) 1989-03-15 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GAA 742/4885NPC1 4398/4885HTR4 2753/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK GAA 940/4885NPC1 4727/4885HTR4 2181/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK GAA 742/4885NPC1 4398/4885HTR4 2753/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GAA 698/4885NPC1 4434/4885HTR4 2458/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK GAA 698/4885NPC1 4434/4885HTR4 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.